Pfizer Global Medical Grants RFP: Improving the Care of Patients with Disorders of Impaired Growth

Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Friday 29th, July 2022

External Deadline: Wednesday 3rd, August 2022


The International Coalition of Organizations Supporting Endocrine Patients (ICOSEP) and Pfizer Global Medical Grants (Pfizer) are collaborating to offer a new grant opportunity seeking proposals to improve the care of patients with disorders of impaired growth.

ICOSEP’s mission is to unite all types of endocrine groups, associations, societies and online entities, into one comprehensive and cooperative global network. This centralized unification, hosted and coordinated by ICOSEP shall, promote, facilitate and transparently share information among all endocrine groups with the goal of uniting our voices regardless of the specific focus held by any one unique organization. This consolidated umbrella of groups, shall enable rare endocrine voices to unite as a cohesive presence and when necessary, take action for the improved care, health, and quality of life for all patients with endocrine related health concerns. Endocrine united.

Pfizer Global Medical Grants (GMG) mission is to support the global healthcare community’s independent initiatives to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Organizations are invited to submit an application addressing the specific gaps in practice as outlined in the specific RFP. For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

Geographic Scope: Global

Clinical Area: Disorders of impaired growth

Link to full RFP: Improving the Care of Patients with Disorders of Impaired Growth

Application Due Date: August 3, 2022

Specific Area of Interest:  It is our intent to support projects that focus on direct patient care to improve patient outcomes for those with pediatric disorders of impaired growth. These may include quality improvement projects focusing on appropriate diagnosis, treatment, management, and comprehensive care of these patients.

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer (

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: June 1, 2022